Comparative Pharmacology
Head-to-head clinical analysis: SYNCURINE versus ZEMURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SYNCURINE versus ZEMURON.
SYNCURINE vs ZEMURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, blocking neurotransmission and causing skeletal muscle paralysis.
Rocuronium is a nondepolarizing neuromuscular blocking agent that competitively binds to nicotinic acetylcholine receptors at the motor endplate, preventing acetylcholine from inducing muscle contraction.
0.1-0.2 mg/kg IV bolus for paralysis, repeat 0.05-0.1 mg/kg as needed; maintenance infusion 0.5-1.5 mcg/kg/min IV.
0.6-1.2 mg/kg IV bolus for intubation; maintenance 0.1-0.2 mg/kg IV as needed for neuromuscular blockade.
None Documented
None Documented
Terminal half-life: 2-5 hours (prolonged with renal impairment; up to 10 hours in severe impairment)
Terminal elimination half-life is approximately 2.3 hours (range 1.7-3.1 hours) in adults with normal renal function. Clinical context: May be prolonged in hepatic or renal impairment.
Primarily renal excretion (50-70% unchanged drug), with biliary/fecal elimination (10-20%)
Primarily renal (70-80% as unchanged drug and metabolites) and biliary (20-30% as unchanged drug and metabolites).
Category C
Category C
Neuromuscular Blocking Agent
Neuromuscular Blocking Agent